PDF
ePub
Citation
Print
Abstract
Background:
The effects of omega-3 polyunsaturated fatty acids (PUFAs) on cerebral vessels have not been clarified until now. Thus we investigated the efficacy of omega-3 PUFAs supplementation on cerebral blood flow velocity and vascular resistance via transcranial doppler (TCD).
Methods:
Consecutive twenty patients (13 male and 7 female) with at least 1 cerebrovascular risk factor or a known cerebrovascular disease were enrolled. Patients were treated with omega-3 PUFAs (1 g, two times per day) for 12 weeks. Cerebral blood flow velocity, resistance index, and pulsatile index were checked before and after 12 weeks of treatment using TCD.
Results:
The change of resistance index in right MCA (from 0.58 ± 0.07 to 0.55 ± 0.07, p = 0.042) and left PCA (from 0.56 ± 0.07 to 0.53 ± 0.06, p = 0.037) showed significant improvement after 12 weeks of omega-3 PUFAs treatment. The changes in other vessels, however, failed to show any significant changes compared to the baseline.
REFERENCES
1.GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999. 354:447–455.
2.Burr ML., Fehily AM., Gilbert JF., Rogers S., Holliday RM., Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989. 2:757–761.
3.Chowdhury R., Stevens S., Gorman D., Pan A., Warnakula S., Chowdhury S, et al. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease systematic review and meta-analysis. BMJ. 2012. 345:e6698.
4.Mackay I., Ford I., Thies F., Fielding S., Bachoo P., Brittenden J. Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease. Atherosclerosis. 2012. 221:514–520.
5.Sanders TA., Hall WL., Maniou Z., Lewis F., Seed PT., Chowienczyk PJ. Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. Am J Clin Nutr. 2011. 94:973–980.
6.Din JN., Archer RM., harding SA., Sarma J., Lyall K., Flapan AD, et al. Effect of w-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers. Heart. 2013. 99:168–174.
7.Tousoulis D., Plastiras A., Siasos G., Oikonomou E., Verveniotis A., Kokkou E, et al. Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome. Atherosclerosis. 2014. 232:10–16.
8.Cho YG., Song HJ., Park BJ. NECA-9 Lipid Lowering Agents Research Group. The comparison of guidelines for management of dyslipidemia and the appropriateness of them in Korea. Korean J Fam Med. 2010. 31:171–181.
9.Santelucia P., Feldman E. The basic transcranial Doppler examination: technique and anatomy. Babikian VL, Wechsler LR, Toole JF, editors. Transcranial Doppler Ultrasonography, 2nd ed. Boston: Butterworth-Heinemann;1999.
10.Gosling RG., King DH. Arterial assessment by Doppler-shift ultrasound. Proc R Soc Med. 1974. 67:447–449.
11.Park KY., Chung PW., Kim YB., Moon HS., Suh BC., Yoon WT. Increased pulsatility index is associated with intracranial arterial calcification. Eur Neurol. 2013. 69:83–88.
12.Kawakami M., Koda M., Murawaki Y., Kawasaki H., Ikawa S. Cerebral vascular resistance assessed by transcranial color Doppler ultrasonography in patients with chronic liver diseases. J Gastroenterol Hepatol. 2001. 16:890–897.
13.Frauchiger B., Schmid HP., Roedel C., Moosmann P., Staub D. Comparison of carotid arterial resistive indices with intima-media thickness as sonographic markers of atherosclerosis. Stroke. 2001. 32:836–841.
14.Korkmaz H., Akbulut M., Ozbay Y., Koc M. A new noninvasive method in evaluating the endothelial function: the measurement of the resistive index after reactive hyperemia of the brachial artery. Echocardiography. 2010. 27:873–877.
15.Saravanan P., Davidson NC., Schmidt EB., Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010. 376:540–550.
16.Harris WS., Rambjor GS., Windsor SL., Diederich D. n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans. Am J Clin Nutr. 1997. 65:459–464.
17.Mozaffarian D., Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011. 58:2047–2067.
18.Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol. 2010. 177:1576–1591.
19.Thies F., Garry JM., Yaqoob P., Rerkasem K., Williams J., Shearman CP, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003. 361:477–485.
20.Kim YJ., Kim OY., Cho Y., Chung JH., Jung YS., Hwang GS, et al. Plasma phospholipid fatty acid composition in ischemic stroke: Importance of docosahexaenoic acid in the risk for intracranial atherosclerotic stenosis. Atherosclerosis. 2012. 225:418–424.
Table 1.
Baseline characteristics
Table 2.
Flow velocity and resistance index change
XML Download